Draig Therapeutics Ltd. launched with a $140 million series A and an AMPA receptor modulator program that has completed phase I and will start a phase II trial in major depressive disorder later in ...
While the COVID pandemic has thankfully been over for some time now, there is still a considerable number of people in the world (about 400 million) suffering from long COVID. Long COVID is a chronic ...
Gait instability and somnolence are the main hindbrain-related adverse effects associated with the inhibition of AMPA receptors (AMPARs). Transmembrane AMPAR regulatory proteins (TARPs) modulate AMPAR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback